How isleukaemia treated?

The treatment of leukaemia varies depending on the patient and type of leukaemia they have.

Acute leukaemia (fast developing) is usually curable with standard treatments, such as chemotherapy.

Chronic leukaemia (slow developing), is often incurablebut treatable. For CLL (a form of chronic leukaemia) some patients are not given treatmentstraight away;however if they do require treatment it will often involve chemotherapy.

The main treatments for leukaemia are:

Chemotherapy: This treatment involves theuse ofdrugs.Chemotherapy drugs either kill cancerous cells or stop them from dividing; they can also kill normal blood cells as a side effect.The type of leukaemia you have will depend on the amount and strength of chemotherapy you are offered, along with other factors such as your age and fitness.

Radiation therapy:Similar to chemotherapy, radiation therapy can be used to destroy the cancerous cells but using radiation waves rather than drugs.Again, the type of leukaemia you have will determine what treatment you're offered. External beam radiation therapy (EBRT) is often used for CLL.It is a fast, painless procedure which usually lasts just a few minutes.

Targeted therapy:Drugs are used to block the growth of cancer cells by disturbing specific molecules in the cells. Targeted therapy can also kill cancer cells by stimulating the patient's immune system to recognise the cells as a threat and consequently kill them.

Biological therapy:This treatment does not target the cancer cells directly, but instead helps to stimulate the body's immune system to act against the cancer. It is also often referred to as "immunotherapy". It is often usedfor patients with CML.

Stem cell or bone marrow transplant: Transplants for stem cells or bone marrow are commonly carried out for patients withacute leukaemia,if chemotherapy does not prove effective.By undergoing a stem cell or bone marrow transplant it can help replenish the healthy bone marrow in patients, and stimulate new growth that restores the immune system. It is usually given to younger, or more healthy patients.

Leukaemia Care, which provides support to individuals and families affected by blood cancer, is one ofthree charities supported by this years Telegraph Christmas Charity Appeal. Our two other charities are Wooden Spoon, which works with Britains rugby community to raise money for sick, disabled and disadvantaged children; and The Silver Line, a 24-hour helpline and support service for lonely elderly people. To make a donation, visit telegraph.co.uk/charity or call 0151 284 1927

Read more:
Leukaemia: what is it, how to spot the warning signs and who is at risk? - The Telegraph

Spinal Cord Stem Cells Comments Off on Leukaemia: what is it, how to spot the warning signs and who is at risk? – The Telegraph | November 3rd, 2019

Pelizaeus-Merzbacher disease is a genetic malady that leaves neurons without their myelin coating. This deficit has devastating consequences for the boysits X-linkedwho have it. These children have severe developmental delay, so they have inability to walk, inability to talk and perform self-care, says Nalin Gupta, a professor of neurological surgery and pediatrics at the University of California, San Francisco (UCSF). Their neurologic function typically does not improve, and usually they actually die during childhood.

About a decade ago, the biotech firm StemCells Inc. was looking for a neurosurgeon to try out an intervention that might finally offer some help for these children. Because Gupta had experience conducting surgical clinical trials in kids with disabilities, the company approached him to see if he could transplant neural stem cells into the brains of boys with Pelizaeus-Merzbacher disease (PMD)an approach that researchers had considered promising for a range of conditions, but which had yet to be proven effective in a clinical trial for any disease. He agreed.

In 2012, Gupta and colleagues reported that four boys with PMD who had received pluripotent neural stem cells in a Phase 1 clinical trial tolerated the procedure, and imaging techniques that indirectly detect myelin indicated they may have had myelination in their brains one year following the transplant. This August, the researchers reported the results of a long-term follow-up study of those patientsall four are still alive at ages 10, 11, 12, and 13. Patients like these who have symptoms of the disease starting at birth typically die in their teens.

Although the researchers could not directly examine myelinationthat would require autopsiesthe imaging evidence is promising. There were some clinical improvements, too, although with such a small number of patients and no control group in a trial designed to examine safety, its hard to know whether they are attributable to the transplant.

We dont actually have a product that we can use even if we wanted to do a Phase 2 study in this disease.

Nalin Gupta, UCSF

Guptas study is the latest report in a series of clinical trials on neural stem cell transplantation, in which pluripotent neural cells taken, in most cases, from the brains of aborted fetuses are expanded in the lab and then injected into the brains or spinal cords of patients with incurable neurological disorders. These include stroke, multiple sclerosis, ALS, spinal injury, and Parkinsons disease. But for all the effort that has gone in to testing these cells, none have been able to work themselves out of trials and into clinical practice.

When asked which of the human clinical trials have been most successful, Steven Goldman, a professor of neurology and neuroscience at the University of Rochester, replies, So far, none of them, right? To date, no Phase 2 trial to evaluate the efficacy of a neural stem cell treatment has been completed, he points out. And scientists, Gupta included, are less-than-ecstatic about the methods and outcomes of the clinical trials that have been done so far.

Goldman, who was not involved in the PMD experiment, calls it by far the most rigorous and well controlled. But that trial can go no further.

Gupta says he and his colleagues felt that there was sufficient evidence from the Phase 1 trial to justify a Phase 2. They cant proceed, however, because StemCells, the company that funded the research and provided the cells, closed in 2016. We dont actually have a product that we can use even if we wanted to do a Phase 2 study in this disease, he says.

Research on other potential uses for neural stem cells are also affected by a lack of momentum. Theres somewhat of a pause in what people are doing in terms of stem cell therapeutics, says Gupta. Treatments for conditions such as spinal cord injury and stroke hold the most interest for their potential societal benefit, he says, but the complexity of the changes that occur when the brain or spinal cord are injuredmeaning regions composed of multiple cell types and networks of connections are just wiped outmake for a challenging repair. Were probably a long way from being able to transplant a structure that will recapitulate the three-dimensional organization and structure of the brain and spinal cord, he says. Trials for diseases with more specific defects might be more successful, he adds, such as multiple sclerosis, which like PMD involves demyelination.

According to Evan Snyder, the director of the Center for Stem Cells and Regenerative Medicine at the Sanford Burnam Prebys Medical Discovery Institute in La Jolla, California, there havent been enough trials, and certainly not enough under ideal circumstances, to know whether neural stem cell transplantation can be an effective treatment in humans. I think the field is too young to know right now if theyre effective. I think the field can just say that theyre safe, says Snyder. To be able to know whether the cells are effective, you really need to be able to put them into an optimal setting where their mechanism of action is optimal, and that kind of trial has never been done yet, he adds.

The animal research that laid the foundation for the PMD study, and other studies on diseases involving the loss or absence of myelination, took place in a mouse model called shiverer. These animals have a mutation that prevents their oligodendrocytes from making myelin, such that their neurons are badly insulated and cannot efficiently conduct electrical signals. The shiverer mice have problems with motor functions and self-care along with seizures. They also have a tremor, hence their name.

In 1999, Snyders lab reported in PNAS that injecting mouse neural stem cells into the brains of shiverer mice led to the remyelination of neurons as well as some tremor reductionmeasured by dipping each mouses tail in ink and noting the size of the stain it left on a piece of graph paper.

Using the model, Goldmans team later transplanted human glial progenitor cellswhich are derived from neural stem cellsinto shiverer mice, generating chimeras in which mouse neurons became insulated with human myelin. The chimeric mice, as Goldman reported in Cell Stem Cell in 2008, survived longer and had improved neurological phenotypes, including fewer seizures, compared with untreated controls. In 2012, StemCells Inc., in collaboration with researchers at Oregon Health & Science University and elsewhere, reported in Science Translational Medicine that transplanting shiverer mice with human neural stem cells resulted in remyelination in the brain. Also in that issue, Gupta and StemCells described the one-year results from the PMD trial, which used the same cells for transplantation.

Neurons (green) and glia (red) differentiated from human neural stem cells in culture. Nuclei are stained blue.

Evan Snyder

The PMD study was not the first trial launched by StemCells Inc. In 2006, the company launched a Phase 1 trial of neural stem cell transplantation in children with Batten disease, a fatal condition in which children are missing a lysosomal storage enzyme. That study was the first study authorized by the FDA for transplantation with neural stem cells into the brain, says Stephen Huhn, a biotech consultant and the former chief medical officer of the company.

The trial, which was completed in 2009, revealed the treatment to be safe, the authors reported in Journal of Neurosurgery: Pediatrics. Autopies on the brains of several kids who died of the disease during the study suggested that in some patients donor cells had both survived and migrated away from the subcortical and ventricular injection sites and into the basal ganglia, among other locations, Huhn says.

The fact that we saw even glimmers of an effect was for us very promising that cellular therapy could well have a place in the treatment of some neurological disorders.

Stephen Huhn, formerly of StemCells Inc.

The stem cells used for this and other StemCells trials were isolated from the brain of a single aborted fetus, expanded as balls of cells called neurospheres, and frozen for later use. Before injection into patients, the cells were thawed, cultured for two weeks, and dissociated, so that what was injected was no longer a neurosphere but a cluster of cells, according to Huhn. Because the neural stem cells were donor-derived, patients were given immunosuppressant drugs for several months following the transplant to prevent rejection.

Using the same procedure and stock of cells, Gupta and colleagues transplanted neural stem cells into the brains of the four boys with PMD in a Phase 1 trial that began in 2009 and ran through 2012the same trial whose long-term follow-up results came out this summer. One year after transplantation, diffusion tensor imagingan MRI-based technique that lets researchers indirectly observe myelinated axonsof the boys brains suggested that myelination had occurred.

From 2012 to 2015, the company ran a Phase 1/2 trial of neural stem cell transplantation for age-related macular degeneration. The treatment proved safe, and there was also evidence of a treatment effecta slowing of the retinal damage called geographic atrophy and improvements in visual functionin some patients, says Huhn.

At the same time, the firm was engaged in a Phase 1/2 trial of stem cell transplantation for patients with injuries to the thoracic region of the spine. The treatment proved safe, and Huhn notes that several participants seemed to have sensory improvement below the level of injury, which would imply that the stem cells were having a treatment effect.

But the companys run of auspicious results did not last forever: Its Phase 2 trial of neural stem cells to treat cervical spinal cord injury, which began in 2014, terminated two years later after an independent review of the emerging data found that the study was unlikely to show a statistically significant treatment effect, Huhn says. For that same reason, a follow-up study on the same patients also ended in 2016, he adds.

At that point, StemCells Inc. shut down. STAT reported that the reason was disappointing results from the spinal cord study.

Despite stopping, the companys work was not in vain, says Huhn, as it demonstrated that the approach is safe and might be worth pursuing. These are challenging disorders, Huhn says, adding that the fact that we saw even glimmers of an effect was for us very promising that cellular therapy could well have a place in the treatment of some neurological disorders.

According to Snyder, who was not involved in the work, the PMD trial suffered from the limitations of the clinical trials system. The unfortunate thing is the way clinical trials are designed, you only get a patient who has failed every other intervention, is very deep into the disease, and almost has no chance of anything changing the course, he says. This problem is not unique to the PMD trial but applies to all neural stem cell clinical trials to date, Snyder says. In the Batten disease trial, for instance, the patients had little hope of recovery, Snyder notes. Three of the six participants had died of their disease by the time the researchers stopped collecting data. Where stem cells are going to be most useful, ultimately, is going to be the early stages of a disease where there are regions that can be rescued, and where the cells are placed in a position where they can distribute themselves throughout the region that needs to be fixed. And no clinical trial has ever met those [criteria].

Although the follow-up PMD study revealed some myelination, there was not a lot of it, notes Goldman, who was not involved in the work. Theres some evidence for local remyelination around the region of the transplants, but there was nothing that was dispersed or broad, and these patients need really widespread remyelination, he says.

Goldman says he believes that there was not more widespread and robust myelination in the PMD patients because of the cell type used. While neural stem cells can give rise to oligodendrocytes, astrocytes, and neurons, they not very efficient at making oligodendrocytes, he says. And, he adds, they do not migrate much, which is necessary for them to have widespread effects. In contrast, human glial progenitor cells, which are produced from neural stem cells and give rise to both oligodendrocytes and astrocytes, are more migratory, says Goldman, and for this reason, the field has shifted away from neural stem cells and toward glial progenitor cells for transplantation. Goldman has trials of his own in the works using a neural stem cell derivative to treat multiple sclerosis and PMD through a company he cofounded, Oscine Therapeutics.

Other trials are currently underway. Researchers at Emory University and the University of Michigan, with funding from the company Neuralstem, have completed a Phase 1 study of neural stem cells to treat ALS and, according to ClinicalTrials.gov, a Phase 2 clinical trial is ongoing. Theres a Phase 2/3 trial of nasally delivered neural stem cells to treat Parkinsons disease enrolling in China. And theres an active Phase 1 trial for Parkinsons disease in Australia using human parthenogenetic neural stem cells derived from unfertilized eggs, rather than fetal tissue.

This year, Snyder received a California Institute for Regenerative Medicine (CIRM) grant to do work leading up to cell-based therapies for babies who are at risk for developing cerebral palsy due to perinatal asphyxia, or oxygen and blood deprivation in the womb, he says. Within the first few days of life, the researchers plan to do brain imaging to identify babies with regions of the brain where cells are injured but not dead, he says, then transplant neural stem cells. The injurys still very fresh and cells are sort of teetering on a knife edge. They can either go on to die or they can go on to live, and the [transplanted] stem cells make factors that push them in the direction to live, Snyder says. If that happens, the prediction is the babies will do much better.

Theres only a short window, when cells are damaged but not dead, during which a neural stem cell transplant can work, he adds. Other trials in older patients with more advanced disease, he suggests, may have missed their optimal treatment windows. Snyder predicts that if the right patients are transplanted with the right neural stem cells at the right time, I think then, under those circumstances, now youre going to start seeing not just safety but real efficacy.

Ashley P. Taylor is a New Yorkbased freelance reporter. Follow her on Twitter@crenshawseedsand read her work atashleyptaylor.com.

Read the original here:
Neural Stem Cell Transplantation Crawls Toward the Clinic - The Scientist

Spinal Cord Stem Cells Comments Off on Neural Stem Cell Transplantation Crawls Toward the Clinic – The Scientist | October 30th, 2019

Massive inflammation and other changes in the striatum, an area of the brain selectively destroyed in Huntingtons disease (HD), are already present before patients develop any symptoms, a study has found.

These findings could help understand how the disease unravels and why this brain region is particularly sensitive to degeneration in individuals with Huntingtons.

The study, The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntingtons disease brain, was published in the journal BMC Medical Genomics.

Huntingtons is a neurodegenerative disease caused by mutations in the huntingtin(HTT) gene and marked by trouble in controlling movement, a progressive loss of thinking ability, and psychiatric problems.

Symptoms, which typically begin when people reach their 30s and 40s, stem from a selective degeneration of certain brain regions, particularly two areas: the basal ganglia, a region deep in the brain thats responsible for functions including movement coordination; and the cortex, the outer and highly twisted layer of the brain which controls thought, behavior, and memory.

Within the basal ganglia, HD targets nerve cells (neurons) of the striatum, especially in two areas known as the caudate nuclei and putamen. These regions can shrink and suffer massive damage as a result of disease progression.

Very little is known about the active disease processes leading to such debilitating symptoms. Obtaining post-mortem brain samples from people with disease-causing mutations who have not yet developed symptoms in other words, still have a largely intact striatum is very rare.

Researchers atBoston University School of Medicine (BUSM) had the opportunity to analyze samples from the striatum more precisely, the caudate nucleus of two HD-positive individuals who had no symptoms at the time of their death.

To pinpoint early drivers of disease, the team compared the activity (expression) of genes those turned on and turned off in the caudate nucleus of these asymptomatic individuals to the prefrontal cortex of 26 symptomatic Huntingtons patients and 56 healthy controls.

Researchers used a high throughput sequencing technology called RNA-Seq to determine gene expression profiles, and a preformed bioinformatics analysis to understand which genes and biological processes were altered.

Our data suggest that the striatum experiences massive inflammation in HD even before symptoms appear, and exhibits a similar gene expression pattern to that observed in prefrontal cortex. Patterns unique to the striatum are also observed, Adam Labadorf, PhD, director of BUs Bioinformatics Nexusand the studys senior author,said in a news release.

In addition to extensive inflammatory processes, the data also suggested that over the diseases course, the striatum undergoes some form of neurogenesis, or the generation of new nerve cells.

While these are only trends that warrant further investigation, researchers propose that active production of neurons could be happening in the striatum during the prodromal phase (before symptom onset) to compensate for the nerve cell loss that precedes symptoms.

The idea that active neurogenesis occurs in the adult brain is controversial, but could lead to exciting discoveries into the innate regenerative capabilities of the central nervous system, Labadorf said.

According to researchers, these findings provide clear evidence that the caudate nucleus is strongly affected in people positive for Huntington disease, before the emergence of any symptoms.

This study presents the most detailed analysis to date of the active disease process in the primarily affected brain region of HD, and although these results do not directly suggest any novel therapies, a better understanding of these processes is likely to lead to them, Labadorfadded.

An important observation was that some genes, like HSPA6, were perturbed across all HD patient samples relative to healthy brains. This set of genes may provide an opportunity to develop prognostic tests for disease progression, the researchers noted.

A robust clinical test measuring disease progression will likely take the form of a panel of key inflammatory and possibly developmental genes measured in the blood or cerebrospinal fluid (the liquid surrounding the brain and spinal cord), they wrote.

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.

Total Posts: 79

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Original post:
Huntington's Marked by Inflammation and Changes in Brain's Striatum Before Symptoms, Study Finds - Huntington's Disease News

Spinal Cord Stem Cells Comments Off on Huntington’s Marked by Inflammation and Changes in Brain’s Striatum Before Symptoms, Study Finds – Huntington’s Disease News | October 30th, 2019

Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery (Nerve Grafting, Neurorrhaphy), By Product (Biomaterials Neurostimulation & Neuromodulation Device), And Segment Forecasts, 2019 - 2026

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery, By Product And Segment Forecasts, 2019 - 2026" - https://www.reportlinker.com/p05807210/?utm_source=GNW

The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7%. Demand for neurological disorder therapies owing to increasing incidence and rising awareness about the same will drive the market. Moreover, government funding and reimbursement policies and uninterrupted technological advances are also projected to help boost the market growth.

In January 2016, the EU Horizon 2020 program funded a research project Autostem, launched by the NUI Galways Regenerative Medicine Institute (REMEDI), costing about USD 6.73 million. This project was to develop a robotic stem cell production factory, having an edge over the old traditional techniques. This technique offers prospects of new therapies for a range of diseases, such as cancers, diabetes, and arthritis. Increased R&D and investments by key companies in emerging countries are also driving the market growth. In July 2018, the Stem Cells Australia (SCA) received USD 3 million for stem cell research from the Medical Research Future Fund (MRFF).

In addition, government and private funded organizations are conducting clinical trials to develop a safe and effective therapy for different neurological disorders, such as Stem Cells in Umbilical Blood Infusion for Cerebral Palsy (Phase II) and usage of Polyethylene glycol (PEG) drug (Phase I) to promote axonal fusion technique to repair peripheral nerve injuries in humans.

Furthermore, in October 2017, Stryker Corporation acquired VEXIM, a France-based medical device company.VEXIMs portfolio is complementary to Strykers Interventional Spine (IVS) portfolio.

With this acquisition, Stryker will strengthen its distribution channels in Eastern Europe, Middle East, Asia, and Latin America. In January 2018, Boston Scientific Corporation received U.S. FDA approval for the first and only Spectra WaveWriter spinal cord stimulator system. This system is used for paresthesia-based therapy.

Further key findings from the study suggest: In 2018, neuromodulation and neurostimulation devices segment led the market due to increased cases of Central Nervous System (CNS) disorders and awareness about mental disorders and available treatments Biomaterials is anticipated to expand at the fastest CAGR during the forecast period due to technological advancements and development of biodegradable polymers that can help enhance spinal stabilization, healing of fractures, and reduce hospitalization North America led the market in 2018 owing to technological advancements and advent of new devices. Government initiatives and funding and increased cases of injured CNS, such as injuries to the spinal cord and brain, were some of the major reasons responsible for the regions growth Asia Pacific is expected to be the fastest-growing market during the forecast period. Growing geriatric population, technological advancements, and many unmet medical needs are some of the factors driving the regions growth In February 2016, Indian scientists working for Revita Life Sciences were approved to conduct clinical trials in 20 clinically dead patients to bring specific parts of their CNS back to life Combination of therapies including cocktail of peptides, nerve stimulation techniques, injecting the brain with stem cells and other techniques that were successful in bringing patients out of coma were to be used Existing medical devices were combined with regenerative biological medicines with an objective to achieve such a complex initiative Some of the key companies include Boston Scientific, Inc.; Stryker Corporation; St. Jude Medical, Inc.; Medtronic plc.; Baxter International, Inc.; AxoGen, Inc.; Polyganics B.V.; Integra; Cyberonics, Inc.; and Lifesciences CorporationRead the full report: https://www.reportlinker.com/p05807210/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

More here:
The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7% - Yahoo Finance

Spinal Cord Stem Cells Comments Off on The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7% – Yahoo Finance | October 25th, 2019

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues and tumors, wherein their toxicity, impurity, and other aspects are studied.

Download Brochure of This Market Report at https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successful stem cell therapy treatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

Go here to read the rest:
Stem Cell Assay Market Analysis On Trends & Need 2025 - Health News Office

Spinal Cord Stem Cells Comments Off on Stem Cell Assay Market Analysis On Trends & Need 2025 – Health News Office | October 25th, 2019

Whether youve been recently diagnosed with multiple sclerosis (MS) or have been living with the condition for a while, chances are youll sometimes hear terms from your healthcare team that are new to you.

The following is a quick, alphabetical guide to the terminology you may need to know as you manage your condition:

Ankle-Foot Orthosis (AFO) A brace designed to support the position of the foot and motion of the ankle to compensate for nerve damage and muscle weakness in the area caused by MS and other movement disorders. An AFO is typically used to stabilize weak limbs or to reposition a limb with contracted muscles into a more normal position.

Autoimmune Disease Your immune system plays a major part of your bodys defense against bacteria and viruses by sending out cells to attack them once they enter your body. However, if you have an autoimmune disease, your immune system mistakenly attacks healthy cells in your body, causing them to weaken or break down. MS is thought to be just one example of an autoimmune disease. It has been suggested that in MS, your immune system may mistakenly attack the cells in your central nervous system.

Axon Long threadlike structures of nerve cells that send impulses to other cells in your body. Research suggests that damage to or loss of these fibers in progressive MS may be linked to worsening disability and more severe progression.

Central Nervous System (CNS) The group of organs in your body that includes the brain, spinal cord, and optic nerves. If you have MS, your bodys immune system may be working against the CNS, producing neurological symptoms such as muscle weakness and vision problems.

Cerebrospinal Fluid (CSF) A clear, colorless liquid that surrounds the brain and spinal cord to protect the CNS and assist in the circulation of nutrients and removal of waste products. In MS, damage to the myelin sheath of nerve cells causes certain types of proteins to be released into the spinal fluid. The presence of these proteins in the CSF, but not in the blood, may point to a diagnosis of MS.

Clinically Isolated Syndrome (CIS) A first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelination (loss of the myelin that covers the nerve cells) in the CNS. People who experience CIS may or may not go on to develop MS. However, when CIS is accompanied by magnetic resonance imaging (MRI)detected brain lesions similar to those found in MS, you have a 60 to 80 percent chance of a second neurologic event and diagnosis of MS within several years, according to the National MS Society.

Cog Fog A commonly used term that refers to the cognitive changes experienced by many people with MS. According to MS Australia, approximately 50 percent of people with the condition will develop some degree of cog fog, or inhibited ability to think, reason, concentrate, or remember. For some, cognitive problems will become severe enough to interfere in a significant way with daily activities.

Corticosteroids (or Steroids) Prescription medication used to treat relapses in relapsing-remitting MS. Your doctor may prescribe intravenous (IV) corticosteroids if the symptoms of your relapse are causing significant problems, like poor vision or difficulty walking. These drugs work by suppressing the immune system and reducing inflammation in the CNS, and they may help relapse symptoms resolve more quickly. But they wont affect your ultimate level of recovery from a relapse or the long-term course of your MS. Methylprednisolone is a commonly used corticosteroid in MS.

Diplopia (or Double Vision) An eye problem in which you see two images of a single object. It may be present when only one eye is open (monocular) or disappear when either eye is closed (binocular). Diplopia is a common symptom of MS, and it occurs because of damage to the optic nerve.

Disease-Modifying Therapies (DMTs) Drugs designed to reduce new relapses, delay progression of disability, and limit new CNS inflammation in people with MS. Although there are multiple DMTs that have been approved by the U.S. Food and Drug Administration (FDA) for use in MS, these drugs generally work by reducing inflammation in nerve cells in theCNS.

Dysarthria A speech disorder caused by neuromuscular impairment and resulting in disturbances in motor control of the muscles used in speech. Its believed the demyelinating lesions in MS may result in spasticity, weakness, slowness, or ataxic incoordination of the lips, tongue, mandible, soft palate, vocal cords, and diaphragm, causing this speech impairment.

Dysphagia (Difficulty Swallowing) A condition that may occur in people with MS, leading to difficulty in eating solid foods or liquids, frequent throat clearing during eating or drinking, a feeling that food is stuck in the throat, or coughing or a choking sensation when eating or drinking. Its the result of nerve damage within the muscles that control swallowing.

Epstein-Barr Virus (EBV) A virus believed to be a possible cause or trigger for MS. Although the exact cause of MS remains unknown, researchers suggest an infectious agent may be involved in its development. Studies have found that antibodies (immune proteins that indicate a person has been exposed to a given virus) to EBV are significantly higher in people who eventually develop MS than in those who dont. Other research has noted that people with a specific immune-related gene and high levels of antibodies to EBV in their blood are 9 times more likely to develop MS than others.

Evoked Potentials A test that measures the speed of nerve messages along sensory nerves to the brain, which can be detected on your scalp using electrodes attached with sticky pads. Its sometimes used in the diagnosis of MS, because nerve damage can slow down the transmission of nerve signals. Evoked potential tests can indicate nerve pathways that are damaged prior to the onset of MS symptoms.

Exacerbation An occurrence of new symptoms or the worsening of old symptoms that may also be referred to as a relapse, attack, or flare-up. Exacerbations can be very mild, or severe enough to interfere with a person's ability to perform day-to-day activities.

Expanded Disability Status Scale (EDSS) A scale used for measuring MS disability and monitoring changes in the level of disability over time. Developed by neurologist John Kurtzke, MD, in 1983, the EDSS scale ranges from 0 to 10 in 0.5-unit increments (scoring is based on a neurological exam) and relies on walking as its main measure of disability. People with an EDSS of 1 have no disability and minimal loss of function, while those with an EDSS of 9.5 are confined to bed and totally dependent on others for functions of daily living.

Foot Drop (or Drop Foot) A symptom of MS caused by weakness in the ankle or disruption in the nerve pathway between the legs and the brain, making it difficult to lift the front of the foot to the correct angle during walking. If you have foot drop, your foot hangs down and may catch or drag along the ground, resulting in trips and falls. Foot drop can be managed with an AFO or other treatments.

Hematopoietic Stem Cell Transplantation (HSCT) A procedure designed to reboot the immune system, the National MS Society says, using hematopoietic (blood cellproducing) stem cells derived from a persons own bone marrow or blood. If your doctor recommends HSCT, youll undergo a chemotherapy regimen before these cells are reintroduced to the body via IV injection, where they will migrate to your bone marrow to rebuild the immune system.

John Cunningham (JC) Virus A common infection completely unrelated to MS that is found in as many as 90 percent of people, according to the UK's MS Trust. JC virus has no symptoms and is normally controlled by the immune system. However, if your immune system is weakened, the JC virus can reactivate, causing potentially fatal inflammation and damage to the brain known as progressive multifocal leukoencephalopathy (PML). Certain MS disease-modifying therapies have been linked with increased risk for PML.

Lhermittes Sign An electric shock-like sensation experienced by some with MS when the neck is moved in a particular way. The sensation can travel down to the spine, arms, and legs.

Lesion (or Plaque) Refers to an area of damage or scarring (sclerosis) in the CNS caused by inflammation in MS. These lesions can be spotted on an MRI scan, with active lesions appearing as white patches. With regular MRIs, a neurologist can tell how active your MS is.

Lumbar Puncture (or Spinal Tap) A procedure used for the collection of cerebrospinal fluid (CSF), sometimes done to help diagnose MS. For this procedure, your doctor will ask you to lie on your side or bend forward while seated, before cleansing an area of your lower back and injecting a local anesthetic. He will then insert a hollow needle and extract a small amount of spinal fluid using a syringe.

Magnetic Resonance Imaging (MRI) The diagnostic tool that currently offers the most sensitive noninvasive way of imaging the brain, spinal cord, or other areas of the body, according to the National MS Society. Its the preferred imaging method for diagnosis of MS and to monitor the course of the disease. MRI uses magnetic fields and radio waves to measure the relative water content in tissues, which is notable in MS because the layer of myelin that protects nerve cell fibers is fatty and repels water. In areas where myelin has been damaged by MS, fat is stripped away and the tissue holds more water. This shows up on an MRI as a bright white spot or darkened area, depending on how the images are made.

McDonald Criteria A guidance used in the diagnosis of MS, authored by an international panel of experts on the condition, originally in 2010. The guidance was updated in 2017. Among the key changes: advising for the use of brain MRI as part of the diagnostic process.

MS Hug A common symptom of MS. If you experience the MS hug, you may feel like you have a tight band around your chest or ribs, or pressure on one side of your torso. Some people find that it is painful to breathe. The MS hug can last for seconds, minutes, hours, or even longer.

Myelin A substance rich in lipids (fatty substances) and proteins that helps form the myelin sheath. In MS, particularly relapsing-remitting MS, an abnormal immune response produces inflammation in the CNS, effectively attacking the myelin in the cells.

Myelin Sheath An insulating layer of fatty substances and proteins that forms around the nerves in body, including those in the CNS. It allows electrical impulses to transmit quickly and efficiently along the nerve cells, but these impulses can be slowed if the sheath is damaged, causing MS.

Neurodegeneration Refers to the process by which the myelin sheath of cells in the CNS is damaged in MS. Its believed to be a major contributor to neurological disability in the condition, and may be the reason immune modulation treatments (disease-modifying therapy) are generally less effective in the progressive MS than in the relapsing-remitting MS.

Neurologist The point person for monitoring your MS treatment and managing MS symptoms. This specialist typically focuses on conditions affecting the CNS.

Neuropathic Pain A type of pain common in MS that results from changes or damage to the myelin sheath and the axons, or nerve fibers, it normally covers. MS-caused neuropathic pain may be chronic, intermittent, or occur only in response to a stimulus.

Neuropsychologist A specialist you may be referred to who helps you manage the cognitive effects of MS. Neuropsychological testing (or testing of the functioning of your brain) involves identifying memory or learning difficulties associated with MS. Cognitive rehabilitation may improve functioning.

Nociceptive Pain Caused by damage to muscles and joints, it can be either acute or chronic, and may not result from MS itself, but be caused by changes in posture or walking or the overuse of assistive devices in those with the condition.

Nystagmus A common eye abnormality in MS, its characterized by involuntary, rhythmic, back-and-forth motion of the eyeball, either horizontally or vertically. For those with nystagmus, the perception of the rhythmic movement of the surrounding stationary world (oscillopsia) can be disorienting and disabling.

Oligoclonal Bands (OCBs) Immunoglobulins, or proteins, that collect in blood plasma or cerebrospinal fluid (CSF). Although not every person with MS has OCBs, their presence can support a diagnosis of MS. Having OCBs is generally associated with a younger age of MS onset and a poorer prognosis.

Optic Neuritis An inflammatory condition that damages the optic nerve, a bundle of nerve fibers that transmits visual information from your eye to your brain, causing pain and temporary vision loss in one eye. Its been linked with nerve damage resulting from MS, and may be among the first symptoms a person with the condition experiences.

Pseudobulbar Affect (PBA) A neurologic effect experienced by roughly 10 percent of people with MS as well as some with Parkinsons disease or amyotrophic lateral sclerosis (ALS), according to the Multiple Sclerosis Association of America (MSAA). Its characterized by sudden, uncontrollable expressions of laughter or crying without an obvious cause, which can be distressing as well as embarrassing to those who experience it. PBA is believed to be a mood disorder related to the disruption of nerve impulses in the CNS, but its different from depression, which is also common in MS.

Pseudoexacerbation A temporary worsening of symptoms without actual myelin inflammation or damage. It is often triggered by other illnesses or infection, exercise, a warm environment, depression, exhaustion, and stress. Urinary tract infection (UTI) is the most common type of infection to cause a pseudoexacerbation.

Sclerosis A general hardening of the body tissue. The term multiple sclerosis refers to the multiple areas of scar tissue often called lesions that develop along affected nerve fibers and that are visible in MRI scans.

Spasticity A symptom of MS that causes your muscles to feel stiff, heavy, or difficult to move. When a muscle spasms, youll experience a sudden stiffening that may cause a limb to jerk. This may be painful.

Trigeminal Neuralgia (or Tic Douloureux) A type of neuropathic pain that occurs on the face (usually on one side only). Its a known symptom of MS, and you may experience it in your cheek; upper or lower jaw; inside the mouth; or in the area around your eyes, ears, or forehead. In MS, its typically caused by damage to the myelin sheath around the trigeminal nerve, which among other functions controls the muscles used in chewing. The condition is triggered by everyday activities, like tensing facial muscles while shaving or when chewing.

Vertigo An intense sensation of the surrounding environment spinning around one. In MS, vertigo is typically caused by growth of an existing lesion or development of a new lesion on the brain stem or cerebellum, the area in the brain that controls balance. It can also be a symptom of a problem with the inner ear, or it can be side effect of medication used to treat MS or other health conditions you may have.

Link:
Speaking Multiple Sclerosis: A Glossary of Common Terms - Everyday Health

Spinal Cord Stem Cells Comments Off on Speaking Multiple Sclerosis: A Glossary of Common Terms – Everyday Health | October 25th, 2019

Image Source : PTI

Children, suffering from DMD, usually die of cardio-respiratory failure. Represtational image

Duchenne Muscular Dystrophy (DMD) is a deadly genetic disorder, 99.9 per cent people suffering from which, die between the age of 13 to 23 years. However, in a first, a 26-year-old patient from Lucknow has survived DMD by regularly taking stem cells for the last five years.

Children, suffering from DMD, usually die of cardio-respiratory failure. But with the stem cell therapy, this patient has not lost muscle power in last five years and heart and lung muscles and the upper half of the body are working well.

Dr. B.S Rajput, the surgeon who is treating this patient, said, "DMD is a type of muscular dystrophy and being a genetic disorder, it is very difficult to treat. Autologous (from your own body) bone marrow cell transplant or stem cell therapy in such cases was started in Mumbai about 10 years back.

Dr Rajput, who was recently appointed as visiting professor at GSVM Medical College, Kanpur, said he has treated several hundred DMD patients and recently this combination protocol was published in the international Journal of Embryology and stem cell research.

The patient's father is elated that his son has maintained well with this treatment and now has even started earning by working on computers.

According to Dr Rajput, this disease is endemic in eastern UP, especially Azamgarh, Jaunpur, Ballia and some of the adjoining districts of Bihar, and one out of every 3,500 male child, suffers from the disease.

Yet the disease is not given as much attention as it should be.

Dr Rajput, who is consultant bone cancer and stem cell transplant surgeon from Mumbai, said though patients in Uttar Pradesh and Bihar get financial support from the Chief Minister's Relief Funds, the treatment of autologous bone marrow cell transplant is not included in the package list of Ayushman Bharat scheme, which deprives many from getting the treatment.

The doctor further informed that efforts are being made to establish the department of regenerative medicine in the medical college, where bone marrow cell transplant and stem cell therapy would be done even for other intractable problems like spinal cord injury, arthritis knee and motor neurone disease.

ALSO READ |Fasting triggers regeneration of stem cells capacity: Study

ALSO READ |UK patient 'free' of HIV after stem cell treatment

Go here to read the rest:
In a first, 26-year-old DMD patient in UP survives with stem cell therapy - India TV News

Spinal Cord Stem Cells Comments Off on In a first, 26-year-old DMD patient in UP survives with stem cell therapy – India TV News | October 25th, 2019

Reading Time: 2 minutesLucknow:

Duchenne Muscular Dystrophy (DMD) is a deadly genetic disorder, 99.9 per cent people suffering from which, die between the age of 13 to 23 years. However, in a first, a 26-year-old patient from Lucknow has survived DMD by regularly taking stem cells for the last five years.

Children, suffering from DMD, usually die of cardio-respiratory failure. But with the stem cell therapy, this patient has not lost muscle power in the last five years and heart and lung muscles and the upper half of the body are working well.

Dr B.S Rajput, the surgeon who is treating this patient, said, DMD is a type of muscular dystrophy and being a genetic disorder, it is very difficult to treat. Autologous (from your own body) bone marrow cell transplant or stem cell therapy in such cases was started in Mumbai about 10 years back.

Dr Rajput, who was recently appointed as visiting professor at GSVM Medical College, Kanpur, said he has treated several hundred DMD patients and recently this combination protocol was published in the International Journal of Embryology and stem cell research.

The patients father is elated that his son has maintained well with this treatment and now has even started earning by working on computers.

According to Dr Rajput, this disease is endemic in eastern UP, especially Azamgarh, Jaunpur, Ballia and some of the adjoining districts of Bihar, and one out of every 3,500 male child, suffers from the disease.

Yet the disease is not given as much attention as it should be.

Dr Rajput, who is consultant bone cancer and stem cell transplant surgeon from Mumbai, said though patients in Uttar Pradesh and Bihar get financial support from the Chief Ministers Relief Funds, the treatment of autologous bone marrow cell transplant is not included in the package list of Ayushman Bharat scheme, which deprives many from getting the treatment.

The doctor further informed that efforts are being made to establish the department of regenerative medicine in the medical college, where bone marrow cell transplant and stem cell therapy would be done even for other intractable problems like spinal cord injury, arthritis knee and motor neurone disease.

Here is the original post:
In a first, 26-yr-old DMD patient in UP survives with stem cell therapy - The Woke Journal

Spinal Cord Stem Cells Comments Off on In a first, 26-yr-old DMD patient in UP survives with stem cell therapy – The Woke Journal | October 23rd, 2019

Analysts expect Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) to report $-0.05 EPS on November, 14.They anticipate $0.02 EPS change or 28.57 % from last quarters $-0.07 EPS. After having $-0.06 EPS previously, Lineage Cell Therapeutics, Inc.s analysts see -16.67 % EPS growth. The stock decreased 0.81% or $0.0079 during the last trading session, reaching $0.9699. About shares traded. Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) has 0.00% since October 22, 2018 and is . It has by 0.00% the S&P500.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company has market cap of $145.14 million. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It has a 4.18 P/E ratio. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries.

More notable recent Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) news were published by: Businesswire.com which released: Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation Business Wire on September 11, 2019, also Businesswire.com with their article: Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells Business Wire published on September 04, 2019, Finance.Yahoo.com published: Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019 Yahoo Finance on September 26, 2019. More interesting news about Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) were released by: Businesswire.com and their article: Lineage Cell Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019 Business Wire published on September 05, 2019 as well as Finance.Yahoo.coms news article titled: Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019 Yahoo Finance with publication date: September 23, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
$-0.05 EPS Expected for Lineage Cell Therapeutics, Inc. (LCTX) - The Lamp News

Spinal Cord Stem Cells Comments Off on $-0.05 EPS Expected for Lineage Cell Therapeutics, Inc. (LCTX) – The Lamp News | October 23rd, 2019

In a first, 26-yr-old DMD patient in UP survives with stem cell therapy

Lucknow, Oct 22 (IANS) Duchenne Muscular Dystrophy (DMD) is a deadly genetic disorder, 99.9 per cent people suffering from which, die between the age of 13 to 23 years. However, in a first, a 26-year-old patient from Lucknow has survived DMD by regularly taking stem cells for the last five years.

Children, suffering from DMD, usually die of cardio-respiratory failure. But with the stem cell therapy, this patient has not lost muscle power in last five years and heart and lung muscles and the upper half of the body are working well.

Dr. B.S Rajput, the surgeon who is treating this patient, said, "DMD is a type of muscular dystrophy and being a genetic disorder, it is very difficult to treat. Autologous (from your own body) bone marrow cell transplant or stem cell therapy in such cases was started in Mumbai about 10 years back.

Dr Rajput, who was recently appointed as visiting professor at GSVM Medical College, Kanpur, said he has treated several hundred DMD patients and recently this combination protocol was published in the international Journal of Embryology and stem cell research.

The patient''s father is elated that his son has maintained well with this treatment and now has even started earning by working on computers.

According to Dr Rajput, this disease is endemic in eastern UP, especially Azamgarh, Jaunpur, Ballia and some of the adjoining districts of Bihar, and one out of every 3,500 male child, suffers from the disease.

Yet the disease is not given as much attention as it should be.

Dr Rajput, who is consultant bone cancer and stem cell transplant surgeon from Mumbai, said though patients in Uttar Pradesh and Bihar get financial support from the Chief Minister''s Relief Funds, the treatment of autologous bone marrow cell transplant is not included in the package list of Ayushman Bharat scheme, which deprives many from getting the treatment.

The doctor further informed that efforts are being made to establish the department of regenerative medicine in the medical college, where bone marrow cell transplant and stem cell therapy would be done even for other intractable problems like spinal cord injury, arthritis knee and motor neurone disease.

--IANS

amita/rtp

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: IANS

See more here:
In a first, 26-yr-old DMD patient in UP survives with stem cell therapy - Outlook India

Spinal Cord Stem Cells Comments Off on In a first, 26-yr-old DMD patient in UP survives with stem cell therapy – Outlook India | October 22nd, 2019

Bhubaneswar: The advanced treatment of using stem cells for treating Autism and other neurological ailments have come as a ray of hope for the people living with some of these ailments. Medical experts working in the sector claim that the use of the technology improved the lives of many.

According to experts who practice stem cell therapy, the results have been overwhelming. Many of the patients have either been able to fight a deadly disease with the help of stem cells while many have been able to improve their quality of lives by using it. However, the technology is still not used widely in state hospitals.

Medical experts claim that stem cells could be used to treat neurological disorders like Autism, cerebral palsy, mental retardation, brain stroke, muscular dystrophy, spinal cord injury, head injury, cerebellar ataxia, dementia, motor neurone disease, multiple sclerosis while it has also been used to treat cancers like blood cancer with the help of bone marrow transplant when assisted by stem cell therapy.

However, treatment of Autism with stem cells is a new developing sector where visible changes are said to have been reported among children treated with this technology. However, the advanced technology which is now confined to only private sector is a bit expensive.

Autistic kids are usually treated with drugs for symptomatic relief, special education, occupational speech and behavioural therapies. In Autism, despite the best available medical and rehabilitative treatments satisfactory relief is still a far cry, said Dr Nandini Gokulchandran, Head Medical Services, NeuroGen Brain and Spine Institute, Mumbai.

Dr Gokulchandran claims that she has treated many cases of Autism in kids with stem cells which helped in overcoming their limited abilities. Under the treatment regime, an insertion procedure is undertaken followed by training to improve the skills and abilities of autistic kids.

Another neurologist, Dr Richa Bansod said that in India it has been reported that 1 in every 250 children have Autism and this number in increasing with better recognition and awareness of the condition. On the other hand, stem cells are now been used to fight deadly diseases.

Dr Joydeep Chakaborty, an oncologist and stem cell expert from HCG Cancer Hospital, Kolkata said, Stem cells and bone marrow transplants are now being used to cure blood cancer in many cases. It is also widely used to treat blood disorders like Thalassemia, Sickle Cell Anaemia and others.

Read the original post:
Stem cells treatment gives hope in fighting Autism, blood disorders - OrissaPOST

Spinal Cord Stem Cells Comments Off on Stem cells treatment gives hope in fighting Autism, blood disorders – OrissaPOST | October 18th, 2019

Cell therapy market size is estimated to grow significantly during the forecast period from 2019 to 2025. The cell therapy industry should witness substantial expansion over the forecast timeframe due to technological advancements coupled with increasing utilization of cell therapy along with gene therapy as treatment to several conditions.

Increasing funding from private organization as well as government to encourage cell therapy clinical trials, inclusion of varied cell types such as mesenchymal stem cells, skeletal muscle stem cells, lymphocytes, dendritic cells, hematopoietic stem cells (HSC) and pancreatic islet cells for cell therapy research will drive market size growth.

Bone marrow transplant or hematopoietic stem cell transplantation is most commonly performed cell therapy. Growing utilization of this therapy for treating conditions such as blood cancer and other hematologic conditions should drive industry growth. Potential application of cell therapy includes treatment for urinary problems, cancers, repairing spinal cord injuries, autoimmune disease, rebuilding damaged cartilage in joints, immune system improvement, neurological disorders and infectious disease. Such wide-ranging applications of cell therapy should drive business growth over the coming years.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/3132

Increasing prevalence of chronic conditions, government assistance and numerous companies investing heavily in stem cell therapy research and development should stimulate industry growth. Proven effectiveness of cell therapy products coupled with rendering favorable guidelines pertaining to cell therapy manufacturing should positively impact industry growth. However, high cost and stringent regulations related to practicing of stem cell therapy will hamper industry growth to certain extent during the forecast period.

Based on therapy type, the industry is segmented into allogenic and autologous therapies. Autologous segment is anticipated to witness significant growth due to lower risk of fatal complications and graft failure resulting in high survival rate should drive segment growth. Moreover, significant investment in autologous cell therapy research by companies such as Vericel Corporation should positively impact growth.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/3132

Applications of cell therapy include cardiovascular, ocular, musculoskeletal, gastrointestinal, oncology, neurological, dermatology, wounds and injuries, and others. Oncology segment is estimated to witness lucrative growth due to strong pipeline including Chimeric Antigen Receptor (CAR) T-cell therapy that has delivered promising results such as full recovery in end-stage patients suffering from acute lymphocytic leukemia during clinical trials.

Based on end-user, the industry is bifurcated into hospitals, diagnostic centers, clinics, research institutes, regenerative medicine centers and others. Stem cell is core component of regenerative medicine. Increasing research conducted by regenerative medicine researchers on variety of stem cell types such as multipotent adult stem cells (hematopoietic stem cells found in umbilical cord blood and mesenchymal stem cells [MSC] found in adipose tissue), along with pluripotent stem cells such as the bioengineered cells called induced pluripotent stem cells (iPSC) should drive segment growth.

North America cell therapy market will witness robust growth during the forecast period due to favorable regulatory framework to promote development of cellular therapy platform and presence of numerous companies engaged in cell therapy research. Rising awareness and growing healthcare expenditure should further propel industry growth.

Large patient population base suffering from chronic conditions along with development of healthcare infrastructure will drive Asia Pacific cell therapy market. Growing inclination towards advanced medicinal therapies will lead to growth of cell therapy market in the region.

Some notable industry players include, Vericel Corporation, Medipost, Cells for Cells, JCR Pharmaceuticals, Osiris Therapeutics, Kolon Tissuegene, NuVasive, Stemedica Cell Technologies, BioNTech IMFS, Anterogen, Pharmicell, Fibrocell Science, Novartis AG, Glaxosmithkline among others. Industry players are investing heavily in cell therapy research to develop innovative product and gain significant market share of lucrative market in future.

Browse more reports:

Coronary Stents Market: https://www.marketwatch.com/press-release/coronary-stents-market-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2025-2019-10-18

Companion Animal Diagnostic Market: https://www.marketwatch.com/press-release/companion-animal-diagnostic-market-industry-growth-analysis-forecast-by-2025-2019-10-18

Read the original here:
Cell Therapy Market outlook with industry review and forecasts - Technology Magazine

Spinal Cord Stem Cells Comments Off on Cell Therapy Market outlook with industry review and forecasts – Technology Magazine | October 18th, 2019

Axcella Health Inc. (NASDAQ:AXLA) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Analyst Recommendations

In next table is delivered Axcella Health Inc. and Neuralstem Inc.s ratings and recommendations.

Axcella Health Inc.s average price target is $22.5, while its potential upside is 330.21%.

Institutional and Insider Ownership

Roughly 0% of Axcella Health Inc. shares are owned by institutional investors while 4.9% of Neuralstem Inc. are owned by institutional investors. Comparatively, insiders own roughly 1% of Neuralstem Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Axcella Health Inc. has stronger performance than Neuralstem Inc.

Summary

Axcella Health Inc. beats on 8 of the 10 factors Neuralstem Inc.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more from the original source:
Comparing of Axcella Health Inc. (AXLA) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly

Spinal Cord Stem Cells Comments Off on Comparing of Axcella Health Inc. (AXLA) and Neuralstem Inc. (NASDAQ:CUR) – MS Wkly | October 17th, 2019

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Table 1 demonstrates Aldeyra Therapeutics Inc. and Neuralstem Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Risk and Volatility

Aldeyra Therapeutics Inc.s 0.5 beta indicates that its volatility is 50.00% less volatile than that of S&P 500. Neuralstem Inc.s 94.00% more volatile than S&P 500 which is a result of the 1.94 beta.

Liquidity

The Current Ratio and a Quick Ratio of Aldeyra Therapeutics Inc. are 9.2 and 9.2. Competitively, Neuralstem Inc. has 3.8 and 3.8 for Current and Quick Ratio. Aldeyra Therapeutics Inc.s better ability to pay short and long-term obligations than Neuralstem Inc.

Institutional and Insider Ownership

Institutional investors held 69.9% of Aldeyra Therapeutics Inc. shares and 4.9% of Neuralstem Inc. shares. Aldeyra Therapeutics Inc.s share held by insiders are 2.2%. Insiders Competitively, held 1% of Neuralstem Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aldeyra Therapeutics Inc. was less bearish than Neuralstem Inc.

Summary

On 9 of the 9 factors Aldeyra Therapeutics Inc. beats Neuralstem Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continued here:
Reviewing Aldeyra Therapeutics Inc. (ALDX)'s and Neuralstem Inc. (NASDAQ:CUR)'s results - MS Wkly

Spinal Cord Stem Cells Comments Off on Reviewing Aldeyra Therapeutics Inc. (ALDX)’s and Neuralstem Inc. (NASDAQ:CUR)’s results – MS Wkly | October 17th, 2019

This article, written byKatharine Sedivy-Haley, University of British Columbia, originally appeared on The Conversation and is republished here with permission:

When I was applying to graduate school in 2012, it felt like stem cells were about to revolutionize medicine.

Stem cells have the ability to renew themselves, and mature into specialized cells like heart or brain cells. This allows them to multiply and repair damage.

If stem cell genes are edited to fix defects causing diseases like anemia or immune deficiency, healthy cells can theoretically be reintroduced into a patient, thereby eliminating or preventing a disease. If these stem cells are taken or made from the patient themselves, they are a perfect genetic match for that individual, which means their body will not reject the tissue transplant.

Because of this potential, I was excited that my PhD project at the University of British Columbia gave me the opportunity to work with stem cells.

However, stem cell hype has led some to pay thousands of dollars on advertised stem cell treatments that promise to cure ailments from arthritis to Parkinsons disease. These treatments often dont help and may harm patients.

Despite the potential for stem cells to improve medicine, there are many challenges as they move from lab to clinic. In general, stem cell treatment requires we have a good understanding of stem cell types and how they mature. We also need stem cell culturing methods that will reliably produce large quantities of pure cells. And we need to figure out the correct cell dose and deliver it to the right part of the body.

Embryonic, 'induced and pluripotent

Stem cells come in multiple types. Embryonic stem cells come from embryos which makes them controversial to obtain.

A newly discovered stem cell type is the induced pluripotent stem cell. These cells are created by collecting adult cells, such as skin cells, and reprogramming them by inserting control genes which activate or induce a state similar to embryonic stem cells. This embryo-like state of having the versatile potential to turn into any adult cell type, is called being pluripotent.

However, induced pluripotent and embryonic stem cells can form tumours. Induced pluripotent stem cells carry a particularly high risk of harmful mutation and cancer because of their genetic instability and changes introduced during reprogramming.

Genetic damage could be avoided by using younger tissues such as umbilical cord blood, avoiding tissues that might contain pre-existing mutations (like sun-damaged skin cells), and using better methods for reprogramming.

Stem cells used to test drugs

For now, safety concerns mean pluripotent cells have barely made it to the clinic, but they have been used to test drugs.

For drug research, it is valuable yet often difficult to get research samples with specific disease-causing mutations; for example, brain cells from people with amyotrophic lateral sclerosis (ALS).

Researchers can, however, take a skin cell sample from a patient, create an induced pluripotent stem-cell line with their mutation and then make neurons out of those stem cells. This provides a renewable source of cells affected by the disease.

This approach could also be used for personalized medicine, testing how a particular patient will respond to different drugs for conditions like heart disease.

Vision loss from fat stem cells

Stem cells can also be found in adults. While embryonic stem cells can turn into any cell in the body, aside from rare newly discovered exceptions, adult stem cells mostly turn into a subset of mature adult cells.

For example, hematopoietic stem cells in blood and bone marrow can turn into any blood cell and are widely used in treating certain cancers and blood disorders.

A major challenge with adult stem cells is getting the right kind of stem cell in useful quantities. This is particularly difficult with eye and nerve cells. Most research is done with accessible stem cell types, like stem cells from fat.

Fat stem cells are also used in stem cell clinics without proper oversight or safety testing. Three patients experienced severe vision loss after having these cells injected into their eyes. There is little evidence that fat stem cells can turn into retinal cells.

Clinical complications

Currently, stem cell based treatments are still mostly experimental, and while some results are encouraging, several clinical trials have failed.

In the brain, despite progress in developing treatment for genetic disorders and spinal cord injury, treatments for stroke have been unsuccessful. Results might depend on method of stem cell delivery, timing of treatment and age and health of the patient. Frustratingly, older and sicker tissues may be more resistant to treatment.

For eye conditions, a treatment using adult stem cells to treat corneal injuries has recently been approved. A treatment for macular degeneration using cells derived from induced pluripotent stem cells is in progress, though it had to be redesigned due to concerns about cancer-causing mutations.

A path of cautious optimism

While scientists have good reason to be interested in stem cells, miracle cures are not right around the corner. There are many questions about how to implement treatments to provide benefit safely.

In some cases, advertised stem cell treatments may not actually use stem cells. Recent research suggests mesenchymal stem cells, which are commonly isolated from fat, are really a mixture of cells. These cells have regenerative properties, but may or may not include actual stem cells. Calling something a stem cell treatment is great marketing, but without regulation patients dont know what theyre getting.

Members of the public (and grad students) are advised to moderate their excitement in favour of cautious optimism.

Katharine Sedivy-Haley, PhD Candidate in Microbiology and Immunology, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read this article:
BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - TimminsToday

Spinal Cord Stem Cells Comments Off on BEYOND LOCAL: Expert recommends ‘path of cautious optimism’ about the future of stem cell treatment – TimminsToday | October 16th, 2019

It hurt Margaret Godfrey to see daughter Rachel Carter in pain, so she painted.

And once the worst pain had passed, Carter needed a way to move forward, so she wrote.

In 2000, at age 24, Carter was diagnosed with multiple sclerosis, a disease where the immune system eats away at the lining of nerves and impairs or disables the brain and central nervous system.

Carter is now a married 43-year-old mother of three who lives in Ridgefield. But when she was diagnosed with MS, it marked a significant shift in her life. The woman who ran marathons, rode a motorcycle to high school and was once a deckhand on a small riverboat cruise ship to prove a point because she was told a woman couldnt hold that job, slowly morphed as her disease altered life.

It started with a fall on vacation during a run. Then falling on runs became more frequent. Gone went the marathons. In came the treadmill. Slowly, over the course of 12 years, the MS progressed and symptoms became debilitating. Running left completely. Neuropathic pain caused her to feel like she was sunburned in the morning, and by the afternoon or evening it felt like third degree burns. Carter left her job in sales in 2013.

I would always end up in tears in the bed, Carter said.

Carter has chronicled her battle with MS, and a stem cell treatment she credits with turning her prognosis around, in a new book called Enduring the Cure: My MS Journey to the Brink of Death and Back. Her mother helped her edit the book, and provided the books cover art. Adrienne van Der Valk also edited the book.

Through pain, Carter and her mother have created art. About five years ago, Carter underwent an experimental stem cell transplant in Seattle to help her rebuild her immune system. Carter lived in Seattle for about three months, while her parents watched two of her children, and the other child lived with an aunt.

As part of the procedure, Carters own stem cells were harvested and then reintroduced to her body after chemotherapy depleted most of her immune system. Its what she described as a rebooting of her whole immune system, in hopes that it would stop attacking her brain and spinal cord. Carter still has her previous brain damage, which impacts her memory and brain power; but so far, the stem cell transplant has improved her condition greatly, she said.

Carter has more energy she used to sometimes not be able to leave bed some days. She also can stand upright and walk easily she used to rely on a walker. And her pain is minimal now, the biggest improvement.

Carters family kept notes during her treatment, and Carter decided to use those, and the memories of her family, to help her write the book with van Der Valk.

Thinking was very fatiguing for Carter, since she still has the brain damage from MS. She could only work about one to two hours on the book at a time. She said writing was frustrating and hard in many ways. Parts of my brain are gone, Carter explained. She said it requires her about 10 times as much brain matter as the average person to process something simple.

Its so much pressure to have something you feel like you have to do, and then you cant do it. I had so little energy, Carter said. I cant explain very well because so many words dont come to me.

In spite of the challenges, Carter feels like sharing her experience will help others because, in life, we all have hard situations, she said.

Godfrey, a 70-year-old painter who lives in Blue River, Ore., found art in the familys experience. She drew inspiration from Gustav Klimt, an Austrian symbolist, who painted in the late 1800s and early 1900s, and created symbolic paintings of her daughter. Godfrey said art makes her an intellectual because of how she has to think about what shes painting. This time she was researching her own child.

Godfrey did a painting of Carter surrounded by old running shoes, a life she had to give up. She did a painting of Carter without her hair, which centered on Carters worries. She did a painting of Carter covered by a quilt with her three kids on it, what kept her going and allowed her to recover. She did a painting of Carter lying in a hospital bed, looking exhausted and resigned, which is the books cover. The final painting in the series, called The Journey Is Not Done, features Carter with hair, months after treatment. It has an unfinished mosaic because Carters journey isnt over.

Creating art is a very meditative thing, Godfrey said. Rather than getting wrapped up in emotions, once I start painting the world is me and paper. All the worries of life disappear. It was a way to enjoy that experience of just being able to throw out my expression, without getting too emotionally tangled up.

More:
Ridgefield woman, her mother write book about battle with MS - The Columbian

Spinal Cord Stem Cells Comments Off on Ridgefield woman, her mother write book about battle with MS – The Columbian | October 16th, 2019

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

In table 1 we can see ZIOPHARM Oncology Inc. and Neuralstem Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has ZIOPHARM Oncology Inc. and Neuralstem Inc.s return on equity, return on assets and net margins.

Volatility and Risk

ZIOPHARM Oncology Inc. has a 2.55 beta, while its volatility is 155.00% which is more volatile than S&P 500. Neuralstem Inc. on the other hand, has 1.94 beta which makes it 94.00% more volatile compared to S&P 500.

Liquidity

ZIOPHARM Oncology Inc. has a Current Ratio of 8.9 and a Quick Ratio of 8.9. Competitively, Neuralstem Inc.s Current Ratio is 3.8 and has 3.8 Quick Ratio. ZIOPHARM Oncology Inc.s better ability to pay short and long-term obligations than Neuralstem Inc.

Analyst Recommendations

The Recommendations and Ratings for ZIOPHARM Oncology Inc. and Neuralstem Inc. are featured in the next table.

ZIOPHARM Oncology Inc. has an average price target of $6.5, and a 51.52% upside potential.

Institutional and Insider Ownership

Roughly 45.3% of ZIOPHARM Oncology Inc. shares are owned by institutional investors while 4.9% of Neuralstem Inc. are owned by institutional investors. ZIOPHARM Oncology Inc.s share owned by insiders are 0.5%. Competitively, Neuralstem Inc. has 1% of its share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year ZIOPHARM Oncology Inc. has 271.12% stronger performance while Neuralstem Inc. has -64.87% weaker performance.

Summary

ZIOPHARM Oncology Inc. beats Neuralstem Inc. on 10 of the 11 factors.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexons synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the original post here:
Contrasting of ZIOPHARM Oncology Inc. (ZIOP) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly

Spinal Cord Stem Cells Comments Off on Contrasting of ZIOPHARM Oncology Inc. (ZIOP) and Neuralstem Inc. (NASDAQ:CUR) – MS Wkly | October 16th, 2019

Cellular therapy is also known as cytotherapy or cell therapy. Cellular therapy (CT) is the transplantation of cellular material into human body to repair or replace damaged tissue and damaged cells. Advancement in technology, development of innovative products, and growth in the number of research activities have helped in the discovery of several types of cells that are likely to be used in the treatment or therapy of various conditions and diseases. Several cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, skeletal muscle stem cells, dendritic cells, pancreatic islet cells, and lymphocytes can be used in cellular therapy. HSC is extensively used in cellular therapy. Cellular therapy is used to treat various types of cancers, infectious diseases, autoimmune diseases, and urinary problems. The therapy also helps patients rebuild damaged cartilage in joints, improve a weakened immune system, and repair spinal cord injuries. Moreover, it also helps treat neurological disorders. Cellular cancer therapy has various approaches as the cell can be designed to stimulate the patients immune system (T cells or natural killer cells) to kill cancer cells, or to replace most of the patients immune system to enhance their immune response to cancer cells, or to directly find and kill the cancer cells.

The global cellular therapy in oncology market has been classified based on cancer type and geography. In terms of cancer type, the market has been categorized into blood cancer, prostate cancer, pancreatic cancer, brain cancer, and other cancer. The blood cancer segment accounts for a major share of cellular therapy in oncology market. Increasing prevalence of prostate cancer is expected propel the segment in the near future. According to WHO statistics, 8.2 million people die each year due to cancer which estimates about 13% of all death worldwide. There are more than 100 types of cancers that require unique diagnoses and therapies. This increases the demand for cellular therapy in oncology in near future.

Geographically, the cellular therapy in oncology market has been segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America dominates the cellular therapy in oncology market followed by Europe. The market in Asia Pacific and Latin America is developing. This trend is expected to continue during the forecast period. Availability of large patient pool, expansion of the health care industry, and rise in government investment to improve the health care industry are anticipated to propel the market in these regions. The cellular therapy in oncology market in countries such as Brazil, China, and India are projected to expand at substantial growth rate during the forecast period due to rise in awareness among the population about the usage of cellular therapy to treat various types of cancers and rapid innovations in cellular therapy.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/cellular-therapy-oncology-market.html

Increasing prevalence of various cancers, affordability of cellular therapy in cancer drugs, high adoption in developed markets, and development of innovative drugs are other factors driving the cellular therapy in oncology market. High competition among existing players, high risks of failure, severity and complications involved in cellular therapy due to misdiagnosis, and lack of awareness among the rural population in underdeveloped and developing economies are likely to inhibit the market.

Major players operating in the cellular therapy in oncology market include Alkem Laboratories Limited, Amgen, Inc., Bayer AG, Sanofi, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Cipla, Inc., Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=37538&source=atm

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37538&source=atm

See the rest here:
Cellular Therapy in Oncology Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2017 2025 - Online News Guru

Spinal Cord Stem Cells Comments Off on Cellular Therapy in Oncology Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2017 2025 – Online News Guru | October 13th, 2019

Both Vericel Corporation (NASDAQ:VCEL) and BioTime Inc. (:) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

We can see in table 1 the earnings per share, gross revenue and valuation of Vericel Corporation and BioTime Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

Volatility and Risk

Vericel Corporation has a 2.72 beta, while its volatility is 172.00% which is more volatile than S&P 500. BioTime Inc. has a 2.81 beta and it is 181.00% more volatile than S&P 500.

Liquidity

Vericel Corporations Current Ratio is 8.5 while its Quick Ratio is 8.2. On the competitive side is, BioTime Inc. which has a 3.5 Current Ratio and a 3.5 Quick Ratio. Vericel Corporation is better positioned to pay off short and long-term obligations compared to BioTime Inc.

Analyst Recommendations

The Recommendations and Ratings for Vericel Corporation and BioTime Inc. are featured in the next table.

Vericel Corporations upside potential currently stands at 48.79% and an $21.5 average price target.

Institutional and Insider Ownership

The shares of both Vericel Corporation and BioTime Inc. are owned by institutional investors at 89% and 43.7% respectively. About 0.5% of Vericel Corporations share are held by insiders. Insiders Comparatively, held 3.9% of BioTime Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Vericel Corporations stock price has smaller growth than BioTime Inc.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the article here:
Vericel Corporation (VCEL) and BioTime Inc. (:) Contrasting side by side - MS Wkly

Spinal Cord Stem Cells Comments Off on Vericel Corporation (VCEL) and BioTime Inc. (:) Contrasting side by side – MS Wkly | October 13th, 2019

Work type: Full-timeDepartment: School of Biomedical Sciences (22600)Categories: Academic-related Staff

Applications are invited for appointment as Post-doctoral Fellow in the School of Biomedical Sciences (Ref.: 498889), to commence as soon as possible for three years, with the possibility of renewal.

Applicants should have a Ph.D. degree in Molecular Biology, Cell Biology, Neurobiology or a related discipline. Preference will be given to those with experience in human neural stem cell culture and vivo spinal injury models. Applicants should also have a good command of both written and spoken English. The appointee will study the therapeutic potential of genetically modified human neural stem cells in rodent spinal cord injury models. Please visit http://www.sbms.hku.hk/staff/martin-chi-hang-cheung or contact Dr. Martin Cheung at mcheung9@hku.hk for further information. Applicants who have responded to the previous advertisement (Ref.: 494003) need not re-apply.

A highly competitive salary commensurate with qualifications and experience will be offered, in addition to annual leave and medical benefits

The University only accepts online application for the above post. Applicants should apply online and upload an up-to-date C.V.Review of applications will start on October 23, 2019 and continue untilJanuary 31, 2020, or until the post is filled, whichever is earlier.

Here is the original post:
Postdoctoral Fellow, School of Biomedical Sciences job with THE UNIVERSITY OF HONG KONG | 182916 - Times Higher Education (THE)

Spinal Cord Stem Cells Comments Off on Postdoctoral Fellow, School of Biomedical Sciences job with THE UNIVERSITY OF HONG KONG | 182916 – Times Higher Education (THE) | October 12th, 2019